These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 35625270)

  • 1. The Comparative Effectiveness of Ceftolozane/Tazobactam versus Aminoglycoside- or Polymyxin-Based Regimens in Multi-Drug-Resistant
    Caffrey AR; Appaneal HJ; Liao JX; Piehl EC; Lopes V; Dillon RJ; Puzniak LA; LaPlante KL
    Antibiotics (Basel); 2022 May; 11(5):. PubMed ID: 35625270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas aeruginosa.
    Pogue JM; Kaye KS; Veve MP; Patel TS; Gerlach AT; Davis SL; Puzniak LA; File TM; Olson S; Dhar S; Bonomo RA; Perez F
    Clin Infect Dis; 2020 Jul; 71(2):304-310. PubMed ID: 31545346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of ceftolozane/tazobactam, alone and in combination with colistin, against multidrug-resistant Pseudomonas aeruginosa in an in vitro biofilm pharmacodynamic model.
    Gómez-Junyent J; Benavent E; Sierra Y; El Haj C; Soldevila L; Torrejón B; Rigo-Bonnin R; Tubau F; Ariza J; Murillo O
    Int J Antimicrob Agents; 2019 May; 53(5):612-619. PubMed ID: 30682497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Utilization study in real clinical practice of ceftolozane/tazobactam vs aminoglycosides and/or colistin in the treatment of multirresistant or extremely resistant Pseudomonas aeruginosa].
    Pinilla-Rello A; Huarte-Lacunza R; Magallón-Martínez A; Cazorla-Poderoso L; Pereira-Blanco O; Pérez-Moreno M; Larrodé-Leciñena I; Martínez-Álvarez RM; López-Calleja AI
    Rev Esp Quimioter; 2021 Oct; 34(5):441-449. PubMed ID: 34154319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative evaluation of early treatment with ceftolozane/tazobactam versus ceftazidime/avibactam for non-COVID-19 patients with pneumonia due to multidrug-resistant Pseudomonas aeruginosa.
    Lodise TP; Obi EN; Watanabe AH; Yucel E; Min J; Nathanson BH
    J Antimicrob Chemother; 2024 Sep; ():. PubMed ID: 39258877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and safety of ceftolozane-tazobactam in the treatment of GNB infections: a systematic review and meta-analysis of clinical studies.
    Chi Y; Xu J; Bai N; Liang B; Cai Y
    Expert Rev Anti Infect Ther; 2023 Feb; 21(2):189-201. PubMed ID: 36629486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of ceftolozane/tazobactam against a collection of Pseudomonas aeruginosa isolates from bloodstream infections in Australia.
    Henderson A; Tan E; McCarthy KL; Paterson DL
    Pathology; 2018 Dec; 50(7):748-752. PubMed ID: 30392710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Dimer, but Not Monomer, of Tobramycin Potentiates Ceftolozane against Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa and Delays Resistance Development.
    Idowu T; Zhanel GG; Schweizer F
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31907191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the In Vitro Susceptibility of Ceftolozane-Tazobactam With the Cumulative Susceptibility Rates of Standard Antibiotic Combinations When Tested Against
    Shortridge D; Pfaller MA; Arends SJR; Raddatz J; DePestel DD; Flamm RK
    Open Forum Infect Dis; 2019 Jun; 6(6):ofz240. PubMed ID: 31263733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Susceptibility of MDR Pseudomonas aeruginosa to ceftolozane/tazobactam and comparison of different susceptibility testing methods.
    Schaumburg F; Bletz S; Mellmann A; Becker K; Idelevich EA
    J Antimicrob Chemother; 2017 Nov; 72(11):3079-3084. PubMed ID: 28961968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant
    Gallagher JC; Satlin MJ; Elabor A; Saraiya N; McCreary EK; Molnar E; El-Beyrouty C; Jones BM; Dixit D; Heil EL; Claeys KC; Hiles J; Vyas NM; Bland CM; Suh J; Biason K; McCoy D; King MA; Richards L; Harrington N; Guo Y; Chaudhry S; Lu X; Yu D
    Open Forum Infect Dis; 2018 Nov; 5(11):ofy280. PubMed ID: 30488041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Human-Simulated Exposures of Ceftolozane-Tazobactam Alone and in Combination with Amikacin or Colistin against Multidrug-Resistant Pseudomonas aeruginosa in an
    Rico Caballero V; Almarzoky Abuhussain S; Kuti JL; Nicolau DP
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29483119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Ceftolozane-Tazobactam vs. Best Alternative Therapy on Clinical Outcomes in Patients with Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Lower Respiratory Tract Infections.
    Holger DJ; Rebold NS; Alosaimy S; Morrisette T; Lagnf A; Belza AC; Coyne AJK; El Ghali A; Veve MP; Rybak MJ
    Infect Dis Ther; 2022 Oct; 11(5):1965-1980. PubMed ID: 36048335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aminoglycoside or Polymyxin Monotherapy for Treating Complicated Urinary Tract Infections Caused by Extensively Drug-Resistant Pseudomonas aeruginosa: A Propensity Score-Adjusted and Matched Cohort Study.
    López Montesinos I; Gómez-Zorrilla S; Palacios-Baena ZR; Prim N; Echeverria-Esnal D; Gracia MP; Montero MM; Durán-Jordà X; Sendra E; Sorli L; Guerri-Fernandez R; Padilla E; Grau S; Horcajada JP;
    Infect Dis Ther; 2022 Feb; 11(1):335-350. PubMed ID: 34860333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world use of ceftolozane/tazobactam: a systematic literature review.
    Puzniak L; Dillon R; Palmer T; Collings H; Enstone A
    Antimicrob Resist Infect Control; 2021 Apr; 10(1):68. PubMed ID: 33832545
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Goodlet KJ; Nicolau DP; Nailor MD
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful Use of Ceftolozane-Tazobactam to Treat a Pulmonary Exacerbation of Cystic Fibrosis Caused by Multidrug-Resistant Pseudomonas aeruginosa.
    Vickery SB; McClain D; Wargo KA
    Pharmacotherapy; 2016 Oct; 36(10):e154-e159. PubMed ID: 27522066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of in vitro activity of ceftazidime/avibactam and ceftolozane/tazobactam against MDR Pseudomonas aeruginosa isolates from Qatar.
    Sid Ahmed MA; Abdel Hadi H; Hassan AAI; Abu Jarir S; Al-Maslamani MA; Eltai NO; Dousa KM; Hujer AM; Sultan AA; Soderquist B; Bonomo RA; Ibrahim EB; Jass J; Omrani AS
    J Antimicrob Chemother; 2019 Dec; 74(12):3497-3504. PubMed ID: 31504587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-Life Use of Ceftolozane/Tazobactam for the Treatment of Bloodstream Infection Due to Pseudomonas aeruginosa in Neutropenic Hematologic Patients: a Matched Control Study (ZENITH Study).
    Bergas A; Albasanz-Puig A; Fernández-Cruz A; Machado M; Novo A; van Duin D; Garcia-Vidal C; Hakki M; Ruiz-Camps I; Del Pozo JL; Oltolini C; DeVoe C; Drgona L; Gasch O; Mikulska M; Martín-Dávila P; Peghin M; Vázquez L; Laporte-Amargós J; Durà-Miralles X; Pallarès N; González-Barca E; Álvarez-Uría A; Puerta-Alcalde P; Aguilar-Company J; Carmona-Torre F; Clerici TD; Doernberg SB; Petrikova L; Capilla S; Magnasco L; Fortún J; Castaldo N; Carratalà J; Gudiol C
    Microbiol Spectr; 2022 Jun; 10(3):e0229221. PubMed ID: 35475683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15).
    Pfaller MA; Bassetti M; Duncan LR; Castanheira M
    J Antimicrob Chemother; 2017 May; 72(5):1386-1395. PubMed ID: 28165526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.